Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C

World Journal of Gastroenterology

Volumn 21, Issue 9, 2015, Pages 2826-2829

  Sakatani, Akihiko ^a   Doi, Yoshinori ^b   Matsuda, Takaaki ^b   Sasai, Yasutaka ^b   Nishida, Naohiro ^b   Sakamoto, Megumi ^b   Uenoyama, Naoto ^b   Matsumoto, Yoshiya ^b   Kinoshita , Kazuo ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OTEMAE HOSPITAL   (Japan)

Author keywords

Anaphylactic shock; Chronic hepatitis C; Peginterferon 2a; Anaphylaxis; Protracted anaphylaxis

Indexed keywords

ADRENALIN; ALANINE AMINOTRANSFERASE; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; CHLORPHENIRAMINE; GLUCOSE; HYDROCORTISONE; IRBESARTAN; LIVER ENZYME; PEGINTERFERON ALPHA2A; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD OXYGEN TENSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DAY HOSPITAL; ENDOCRINE FUNCTION TEST; ERYTHEMA; FEVER; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; MALE; MIDDLE AGED; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTRACTED ANAPHYLAXIS; PRURITUS; RESERVOIR BAG; CHEMICALLY INDUCED; DRUG HYPERSENSITIVITY; HEPATITIS C, CHRONIC; TIME FACTOR;

ANAPHYLAXIS; ANTIVIRAL AGENTS; DRUG HYPERSENSITIVITY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 84925450539     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i9.2826     Document Type: Article

References (16)

1. Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986; 78: 76-83 [PMID: 3722636 DOI: 10.1016/0091-6749(86)90117-x].
2. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol 2005; 95: 217-226; quiz 226, 258 [PMID: 16200811 DOI: 10.1016/s1081-1206(10)61217-3].
3. Luskin AT, Luskin SS. Anaphylaxis and Anaphylactoid Reactions: Diagnosis and Management. Am J Ther 1996; 3: 515-520 [PMID: 11862283 DOI: 10.1097/00045391-199607000-00007].
4. Widmark JM. Imaging-related medications: a class overview. Proc (Bayl Univ Med Cent) 2007; 20: 408-417 [PMID: 17948119].
5. Ciesielski-Carlucci C, Leong P, Jacobs C. Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles. Am J Clin Oncol 1997; 20: 373-375 [PMID: 9256892 DOI: 10.1097/00000421-199708000-00010].
6. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wüthrich B; EAACI (the European Academy of Allergology and Cinical Immunology) nomenclature task force. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-824 [PMID: 11551246 DOI: 10.1111/j.1398-9995.2001.00002.x-i1].
7. Roche Copr. Package insert for Pegasys(Interferon alpha-2a). Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/103964s5154lbl.pdf.
8. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47 [PMID: 8834023 DOI: 10.1016/s0168-8278(96)80184-x].
9. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291 [PMID: 8895006 DOI: 10.1016/s0168-8278(96)80113-9].
10. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 212-223 [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21].
11. Cortellini G, Amadori A, Comandini T, Corvetta A. Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests. Eur Ann Allergy Clin Immunol 2013; 45: 181-182 [PMID: 24129047].
12. Corona T, Leon C, Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology 1999; 52: 425 [PMID: 9932977 DOI: 10.1212/wnl.52.2.425-a].
13. Kemp SF. The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms? Curr Allergy Asthma Rep 2008; 8: 45-48 [PMID: 18377774 DOI: 10.1007/s11882-008-0009-7].
14. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371-376 [PMID: 15316518 DOI: 10.1016/j.jaci.2004.04.029].
15. Lee S, Hess EP, Nestler DM, Bellamkonda Athmaram VR, Bellolio MF, Decker WW, Li JT, Hagan JB, Manivannan V, Vukov SC, Campbell RL. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 2013; 131: 1103-1108 [PMID: 23453138 DOI: 10.1016/j.jaci.2013.01.011].
16. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120: 1378-1381 [PMID: 17936893 DOI: 10.1016/j.jaci.2007.09.022].